NCT02560688View on ClinicalTrials.gov

Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Drug Interaction
Interventions
DRUG

DS-1040b

20 mg single 12-hour intravenous infusion

DRUG

Clopidogrel

Clopidogrel (Plavix) administered orally 300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5

Trial Locations (1)

NW10 7EW

Hammersmith Medicines Research, London

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY